Mumbai-based pharma manufacturer FDC has received an approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Ciprofloxacin Ophthalmic Solution.


</p><tr><td><p class='TableClas'></p><P class='TableClas'><DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>Ciprofloxacin Ophthalmic Solution is a broad spectrum antibiotic used for ocular surface infections.</P>
</p><p class='TableClas'>The Company had recently received approval for Timolol Maleate Ophthalmic Solution. Another ANDA ofloxacin ophthalmic solution is in the final stages of approval.</P>
</p><p class='TableClas'></p></table>


FDC gets approval for Ciprofloxacin solution

Also Read

NYSE Euronext acquires 5 % equity in MCX

Shri Lakshmi plans Rs 350 crore capex

P&G sets up R&D centre in Bangalore

Fly to airport on Deccan`s limos

Ozone Media gets $4 mn from IDG Ventures

Explore News